Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With Hepatitis C and Human Immunodeficiency Virus

Trial Profile

Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With Hepatitis C and Human Immunodeficiency Virus

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms CO13Hepavih
  • Most Recent Events

    • 01 Aug 2023 Status changed from active, no longer recruiting to completed.
    • 13 Aug 2020 Results (n=2641) comparing SVR rates as well as risk of all-cause death, liver-related and non-liver-related deaths, liver-related events, and non-liver-related cancers, between HIV/HCV co-infected and HCV mono-infected from two studies (NCT03324633 & NCT01953458), published in the Journal of Hepatology.
    • 11 Mar 2020 Results (n=2641) from two clinical studies: ANRS CO22 HEPATHER and ANRS CO13 HEPAVIH assessing HIV Coinfection and Risk of Morbidity and Mortality in HCV patients were presented at the 27th Conference on Retroviruses and Opportunistic Infections
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top